Olodaterol (BI 1744)
1222.14
Phase 3 small_molecule completed
Quick answer
Olodaterol (BI 1744) for Pulmonary Disease, Chronic Obstructive is a Phase 3 program (small_molecule) at Boehringer Ingelheim with 2 ClinicalTrials.gov record(s).
Program details
- Company
- Boehringer Ingelheim
- Indication
- Pulmonary Disease, Chronic Obstructive
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- completed